/PTGX
PTGX Stock - Protagonist Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$86.05+0.30%
+$0.26 (+0.30%) • Dec 19
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.87
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).72
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.32
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+11.0%upside
Target: $95.52
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PTGX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$85.19 – $86.91
TARGET (TP)$95.50
STOP LOSS$79.17
RISK/REWARD1:1.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.19
52W High$96.54
52W Low$33.70
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $434.43M | $60.00M | $26.58M | $27.36M | $28.63M |
| Gross Profit | $434.43M | $60.00M | $26.58M | $27.36M | $28.63M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $252.84M | $-93,652,000 | $-131,373,000 | $-125,845,000 | $-64,516,000 |
| Net Income | $275.19M | $-78,955,000 | $-127,393,000 | $-125,551,000 | $-66,150,000 |
| Net Margin | 63.3% | -131.6% | -479.3% | -458.9% | -231.1% |
| EPS | $4.47 | $-1.39 | $-2.52 | $-2.65 | $-1.92 |
Company Overview
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
89%
Hold / Neutral
1
11%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
8 Bullish1 Neutral/Bearish
Price Targets
$55
Average Target
↓ 36.4% Downside
Now
$21
Low
$55
Average
$73
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 17th 2025 | Barclays | Initiation | Overweight | $72 |
| September 12th 2025 | Leerink Partners | Initiation | Outperform | $73 |
| June 17th 2025 | Citigroup | Initiation | Buy | $72 |
| December 6th 2024 | Goldman | Initiation | Neutral | $47 |
| December 6th 2024 | BMO Capital Markets | Initiation | Outperform | $62 |
| November 5th 2024 | Wedbush | Initiation | Outperform | $58 |
| September 24th 2024 | TD Cowen | Initiation | Buy | $65 |
| September 9th 2024 | Truist | Initiation | Buy | $60 |
| October 30th 2023 | CapitalOne | Initiation | Overweight | $32 |
| May 25th 2023 | Jefferies | Resumed | Buy | $40← $30 |
| August 25th 2022 | JMP Securities | Initiation | Mkt Outperform | $21 |
Earnings History & Surprises
PTGXBeat Rate
61%
Last 18 quarters
Avg Surprise
+274.5%
EPS vs Estimate
Beats / Misses
11/6
1 met exactly
Latest EPS
$-0.62
Q4 2025
EPS Surprise History
Q1 24
+1425.1%
$0.44vs$0.03
Q2 24
+173.9%
$3.26vs$1.19
Q3 24
0.0%
$-0.50vs$-0.50
Q4 24
+8.5%
$-0.54vs$-0.59
Q1 25
+3200.0%
$1.98vs$0.06
Q2 25
+62.0%
$-0.19vs$-0.50
Q3 25
-3.8%
$-0.55vs$-0.53
Q4 25
-5.1%
$-0.62vs$-0.59
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 20, 2026 | $-0.53 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.59 | $-0.62 | -5.1% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.53 | $-0.55 | -3.8% | ✗ MISS |
Q2 2025 | May 6, 2025 | $-0.50 | $-0.19 | +62.0% | ✓ BEAT |
Q1 2025 | Feb 21, 2025 | $0.06 | $1.98 | +3200.0% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.59 | $-0.54 | +8.5% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.50 | $-0.50 | 0.0% | = MET |
Q2 2024 | May 7, 2024 | $1.19 | $3.26 | +173.9% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $0.03 | $0.44 | +1425.1% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-0.68 | $-0.58 | +14.7% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.65 | $-0.68 | -4.6% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.69 | $-0.67 | +2.9% | ✓ BEAT |
Q1 2023 | Mar 15, 2023 | $-0.67 | $-0.69 | -3.0% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.94 | $-0.64 | +31.9% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.99 | $-0.84 | +15.2% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-0.67 | $-0.43 | +35.8% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-0.79 | $-0.77 | +2.5% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $-0.67 | $-0.70 | -4.5% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-0.62 | $-0.69 | -11.3% | ✗ MISS |
Latest News
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $108
📈 PositiveBenzinga•Dec 17, 2025, 05:54 PM•Also:
Citigroup Maintains Buy on Protagonist Therapeutics, Raises Price Target to $115
📈 PositiveBenzinga•Dec 8, 2025, 07:43 PM•Also:
Reported Saturday, Protagonist Therapeutics And Takeda Highlight VERIFY And THRIVE Data Showing Long-Term Hematocrit Control And Reduced Therapeutic Phlebotomy In PV At ASH 2025
📈 PositiveBenzinga•Dec 8, 2025, 09:05 AM•Also:
Citigroup Maintains Buy on Protagonist Therapeutics, Raises Price Target to $98
📈 PositiveBenzinga•Nov 10, 2025, 09:56 PM•Also:
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $88
📈 PositiveBenzinga•Nov 7, 2025, 03:47 PM•Also:
Citizens Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $102
📈 PositiveBenzinga•Nov 7, 2025, 02:13 PM
Protagonist Therapeutics Q3 EPS $(0.62) Beats $(0.63) Estimate, Sales $4.712M Beat $3.636M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 09:38 PM
Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $88
📈 PositiveBenzinga•Oct 28, 2025, 04:00 PM
Wedbush Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $86
📈 PositiveBenzinga•Oct 28, 2025, 01:11 PM
BTIG Reiterates Buy on Protagonist Therapeutics, Maintains $82 Price Target
📈 PositiveBenzinga•Oct 28, 2025, 09:23 AM
Protagonist Therapeutics Announces New Data From Two Studies Of Icotrokinra, Investigational Targeted Oral Peptide That Precisely Blocks IL-23 Receptor
📈 PositiveBenzinga•Oct 27, 2025, 11:41 AM
Citigroup Maintains Buy on Protagonist Therapeutics, Raises Price Target to $96
📈 PositiveBenzinga•Oct 17, 2025, 03:29 PM•Also:
Protagonist Therapeutics falls amid a report J&J deal price may be lower
📉 NegativeSeeking Alpha•Oct 13, 2025, 05:24 PM•Also:
Key deals this week: Protagonist Therapeutics, Bristol Myers, Novo Nordisk, Fifth Third Bancorp and more
➖ NeutralSeeking Alpha•Oct 11, 2025, 07:15 PM•Also: , ,
Protagonist Therapeutics shares are trading higher after the Wall Street Journal reported Johnson & Johnson is in discussions to acquire the company.
📈 PositiveBenzinga•Oct 10, 2025, 05:21 PM•Also:
Protagonist Therapeutics Shares Resume Trade
➖ NeutralBenzinga•Oct 10, 2025, 03:33 PM
Protagonist Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 9.40%
📈 PositiveBenzinga•Oct 10, 2025, 03:15 PM
'Johnson & Johnson In Talks To Buy Protagonist Therapeutics; The Two Companies Are Already Codeveloping A Treatment For Ulcerative Colitis' - WSJ Exclusive
📈 PositiveBenzinga•Oct 10, 2025, 03:15 PM•Also:
HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $80 Price Target
📈 PositiveBenzinga•Oct 8, 2025, 10:21 AM
Protagonist Therapeutics' Oral IL-23 Blocker Icotrokinra Meets Phase 2b Goals In Ulcerative Colitis; Phase 3 Trials Set For Q4 2025
📈 PositiveBenzinga•Oct 7, 2025, 12:12 PM
Frequently Asked Questions about PTGX
What is PTGX's current stock price?
Protagonist Therapeutics, Inc. (PTGX) is currently trading at $86.05 per share. The stock has moved +0.30% today.
What is the analyst price target for PTGX?
The average analyst price target for PTGX is $95.50, based on 1 analyst.
What sector is Protagonist Therapeutics, Inc. in?
Protagonist Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PTGX's market cap?
Protagonist Therapeutics, Inc. has a market capitalization of $5.38 billion, making it a mid-cap company.
Does PTGX pay dividends?
No, Protagonist Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACLX
Arcellx, Inc.
$63.96
Mkt Cap: $3.5B
AKRO
Akero Therapeutics, Inc.
$54.65
Mkt Cap: $4.5B
ALKS
Alkermes plc
$28.45
Mkt Cap: $4.7B
CRNX
Crinetics Pharmaceuticals, Inc.
$48.01
Mkt Cap: $4.6B
IMVT
Immunovant, Inc.
$26.68
Mkt Cap: $4.7B
KYMR
Kymera Therapeutics, Inc.
$83.99
Mkt Cap: $6.0B
NAMS
NewAmsterdam Pharma Company N.V.
$35.11
Mkt Cap: $4.0B
PTCT
PTC Therapeutics, Inc.
$78.57
Mkt Cap: $6.3B
TGTX
TG Therapeutics, Inc.
$30.98
Mkt Cap: $4.9B
VKTX
Viking Therapeutics, Inc.
$35.19
Mkt Cap: $4.0B
Explore stocks similar to PTGX for comparison